CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University.
CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys is developing products to aid in the detection of breast cancer at its earliest stages including in conditions such as DCIS. Barrett`s esophagus may be a precursor to cancer in some patients. CS-Keys may help physicians identify patients at greatest risk.
CS-Keys technology appears to apply well to the following: Prostate, Ovarian, Pancreatic, and Colorectal cancers. CS-Keys has established a pipeline of several novel cancer diagnostic tests based on caPCNA antibody technology. The caPCNA Key Stain™ is an immunohistochemistry stain to be used as an aid to pathologists in examining tissue biopsies where cancer is suspected. The caPCNA ELISA uses a “sandwich” technique to detect the presence of caPCNA in the sample. This product will be used to monitor patient remission status. caPCNA can also be applied to other diagnostic applications including cytology, immunoflorescence and advance imaging probes.